Method for the production of bacterial toxins

Details Method for the production of bacterial toxins Method for the production of bacterial toxins

2001-04-04

2004-02-03

Housel, James (Department: 1648)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using a micro-organism to make a protein or polypeptide

C435S071100, C435S244000, C435S252310, C424S093100, C424S093460

Reexamination Certificate

active

06686180

ABSTRACT:

REFERENCE TO SEQUENCE LISTING, TABLES OR COMPUTER PROGRAM LISTING
A Sequence Listing in computer readable format is included herewith.
BACKGROUND OF THE INVENTION
The present invention relates to increasing bacterial toxin production using methods and compositions that reduce, or eliminate, the accumulation of intracellular and extracellular toxin expression inhibitors. Specifically, the present invention related to methods and compositions for reducing or elimination the accumulation of Bordetella species toxin expression inhibitors. More specifically, the present invention relates to the high yield production of pertussis toxin, pertactin, adenylate cyclase toxin-hemolysin, filamentous hemagglutinin and other toxins.
Pertussis toxin (PT) is one of the various components produced by virulent
B. pertussis
, the microorganism that causes whooping cough. Whooping cough is a serious infection of the respiratory system that at one time was responsible for the death of 5,000 to 10,000 people in the United States each year. Since the advent of the whooping cough vaccine the number of whooping cough related deaths has been reduced to less than 20 annually. Currently, about 50% of all whooping cough infections occur in children less than 1 year old, and only 15% occur in children over than 15 years old. Kids Health.org (visited Mar. 23, 2000) <http://kidshealth.org/parent/common/whooping_cough.html>.
PT is a major protective antigen in the vaccine against whooping cough. Other components of interest produced by
B. pertussis
are filamentous hemagglutinin, heat labile toxin, adenylate cyclase and the like, which may also play important role as protective antigens. Large-scale production of these components, which are useful as diagnostic or chemical reagents and in the preparation of vaccines, requires large-scale cultivation of the microorganism. However,
B. pertussis
is a fastidious organism that has proved difficult to grow in large fermentors. Older methods for the culture of
B. pertussis
employ cultivation in stationary culture or in fermentors. Growth in a stationary culture is labor intensive, while cultivation on a fermentation scale requires vortex stirring and surface aeration. As a result, the effective volume of the fermentor is reduced and modification of the fermentor for growth of pertussis is often necessary. Furthermore, the quantities of PT produced during fermentation under these conditions are variable and often low.
U.S. Pat. No. 5,338,670 discloses a method for the production of
B. pertussis
in the presence of an iron salt, namely ferrous sulfate. While high iron content supports greater bacterial growth, it suppresses the production of PT. By adjusting the iron content of modified Stainer-Scholte media to 10% of the recommended concentration, the production of PT was optimized.
The present invention seeks to improve the yield of PT obtained from
B. Pertussis
by (1) introducing a soluble salt into the growth medium that sequesters sulfate (SO
4
2−
) and/or (2) employing a
B. Pertussis
cysteine desulfinase knockout mutant.
BRIEF SUMMARY OF THE INVENTION
The present invention is based upon the discovery that bacterial toxin expression inhibitors accumulate in culture media and thus significantly reduce toxin production. Moreover, the present invention is based on the findings that suppressing or eliminating toxin expression inhibitors can significantly up regulate toxin expression. Non-limiting examples of the present invention are disclosed using Bordetella sp., specifically,
B. Pertussis
and/or
B. bronchiseptica
which produce pertussis toxin (PT) and pertactin respectively. However, it is understood, that higher bacterial toxin levels can be achieved in other bacterial culture systems using the teachings of the present invention including but not limited to adenylate cyclase toxin-hemolysin, and filamentous hemagglutinin.
Generally, the present invention is exemplified by disclosing methods and compositions used to cultivate
B. Pertussis
that eliminate, or reduce, intracellular and extracellular PT inhibitor accumulation resulting in significant PT production increases.
In one embodiment of the present invention methods and compositions for preparing novel culture media that support
B. Pertussis
growth and prevent or decrease PT inhibition expression by sulfate anions are disclosed. These media compositions and related methods include, but are not limited to, admixing a
B. Pertussis
culture medium with an effective amount of one or more soluble metal salts that form substantially insoluble complexes with sulfate anions.
In another embodiment of the present invention culture media that support
B. pertussis
growth comprising an amount of one or more soluble salts that form substantially insoluble complexes with PT inhibitors, wherein said amount prevents or reduces the inhibition of PT expression are provided. Specifically, soluble metal salts are disclosed that form substantially insoluble complexes with sulfate anions.
Other embodiments of the present invention include
B. Pertussis
culture media and methods for making and using same that reduce PT inhibitors by limiting or eliminating media constituents that contribute to PT inhibitor accumulation. Specifically, in one embodiment of the present invention cysteine concentration is reduced.
The invention also relates to methods and compositions for producing PT comprising cultivating
B. Pertussis
under conditions that eliminate, or reduce, the accumulation of PT inhibitors in the culture media resulting in significant PT production increases and isolating the PT from the culture medium.
In yet another embodiment of the present invention PT production is enhanced using
B. Pertussis
cysteine desulfinase knockout mutants. In one embodiment of the present invention methods of producing PT comprising growing a
B. Pertussis
cysteine desulfinase knockout mutant in a
B. Pertussis
culture medium, and isolating the PT from the culture medium are provided.


REFERENCES:
patent: 4950599 (1990-08-01), Bertling
patent: 4965205 (1990-10-01), Quentin-Millet et al.
patent: 5272071 (1993-12-01), Chappel
patent: 5338670 (1994-08-01), Sekura et al.
patent: 5460941 (1995-10-01), Camerini-Otero et al.
patent: 5557032 (1996-09-01), Mak
patent: 5612205 (1997-03-01), Kay et al.
patent: 5614396 (1997-03-01), Bradley et al.
patent: 5616491 (1997-04-01), Mak et al.
patent: 5777195 (1998-07-01), Fienberg et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5948653 (1999-09-01), Pati et al.
patent: 5965443 (1999-10-01), Reznikoff et al.
patent: 6015676 (2000-01-01), Lin et al.
patent: 6031149 (2000-02-01), Chambon et al.
Andresen, L.O., “Studies on the effect of divalent metal ions in exfoliative toxins fromStaphylococcus hycius:indications of ExhA and ExhB being Metalloproteins,” FEMS Immunology and Medical Microbiology, 23:295-301 (1999).*
Frohlich et al., Journal of Biotechnology 39: 205-219 (1995).

Affiliated with

Also associated with

Rating

Method for the production of bacterial toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for the production of bacterial toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the production of bacterial toxins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3345482